Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 8/20 | 0.70 |
| ▸ | THRB | P10828 | 8/20 | 0.70 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | HSD17B3 | P37058 | 5/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.61 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.61 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9077274 | 1.00 | THRA (0.70) | THRATHRBHAO1L3MBTL1HSD17B3 | |
| SCHEMBL9077717 | 1.00 | THRA (0.70) | THRATHRBHAO1L3MBTL1HSD17B3 | |
| SCHEMBL9075714 | 1.00 | THRA (0.70) | THRATHRBHAO1L3MBTL1HSD17B3 | |
| SCHEMBL9076086 | 1.00 | THRA (0.70) | THRATHRBHAO1L3MBTL1HSD17B3 | |
| SCHEMBL9075808 | 1.00 | THRA (0.70) | THRATHRBHAO1L3MBTL1HSD17B3 | |
| SCHEMBL9078370 | 1.00 | THRA (0.70) | THRATHRBHAO1L3MBTL1HSD17B3 | |
| SCHEMBL28276142 | 1.00 | THRA (0.70) | THRATHRBHAO1L3MBTL1HSD17B3 | |
| SCHEMBL9077531 | 0.98 | THRA (0.68) | THRATHRBHAO1L3MBTL1HSD17B3 | |
| SCHEMBL9078298 | 0.97 | THRA (0.70) | THRATHRBHAO1L3MBTL1S1PR1 | |
| SCHEMBL9077548 | 0.95 | THRA (0.68) | THRATHRBHAO1L3MBTL1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481743-B1 | LPA receptor agonists and antagonists and methods of use | UNIV TENNESSEE RES FOUND (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2433946-B1 | LPA receptor agonists and antagonists and methods of use | UNIV TENNESSEE RES FOUNDATION (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2262371-B1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS | RXBIO INC (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2481743-A1 | LPA receptor agonists and antagonists and methods of use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120135967-A1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | MILLER DUANE D (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2433946-A1 | LPA receptor agonists and antagonists and methods of use | University of Tennessee Research Foundation (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120010424-A1 | LPA Receptor Agonists and Antagonists | RXBIO INC. | 2012-01-12 | — | — | US | disclosed |
| EP-1678096-B1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES FOUNDATION (US) | 2012-01-04 | — | — | EP | disclosed |
| US-7947665-B2 | lysophosphatidic acid receptor modulator; thiophosphoric acid O-[7-(4-octyl-phenyl)-heptyl] ester; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | MILLER DUANE D | 2011-05-24 | — | — | US | disclosed |
| US-20080090783-A1 | lysophosphatidic acid receptor modulator; thiophosphoric acid O-[7-(4-octyl-phenyl)-heptyl] ester; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | MILLER DUANE D | 2008-04-17 | — | — | US | disclosed |
| US-7217704-B2 | LPA receptor agonists and antagonists and methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-05-15 | — | — | US | disclosed |
| US-5504244-A | 3-(4-N-PENTYLPHENYLACYL)BENZOIC ACID OR SALT OR ESTER | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1996-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010424-A1 | LPA Receptor Agonists and Antagonists | LPAR1, LPAR2, LPAR4 | THRA 1287/4885THRB 1099/4885HAO1 572/4885 |
| US-20120135967-A1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | LPAR1, LPAR2, LPAR4 | THRA 1139/4885THRB 1296/4885HAO1 964/4885 |
| US-20080090783-A1 | lysophosphatidic acid receptor modulator; thiophosphoric acid O-[7-(4-octyl-phenyl)-heptyl] ester; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | LPAR1, LPAR4, LPAR2 | THRA 461/4885THRB 755/4885HAO1 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.